Xenetic to acquire Santersus in all-stock deal; combined company to trade as SNTS

Xenetic Biosciences, Inc.

Share exchange: Xenetic acquires all Santersus shares; Santersus holders to own ~85% of combined company.
Combined company to rename Santersus Bio, Inc. and list on Nasdaq under ticker SNTS.
Post-close board: 8 members (6 Santersus, 2 Xenetic); Santersus CEO James Ladtkow to lead.
Deal includes $500,000 termination fee and 180-day lock-up for officers/directors/stockholders.
Pipeline: four first-in-class programs incl. sepsis and SLE with FDA Breakthrough Device Designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.